Prothena Co. PLC (NASDAQ:PRTA) shares shot up 1.4% during mid-day trading on Friday . The stock traded as high as $50.92 and last traded at $50.05, with a volume of 175,804 shares. The stock had previously closed at $49.38.

Several brokerages have recently issued reports on PRTA. Credit Suisse Group AG reiterated a “buy” rating on shares of Prothena Co. PLC in a research note on Wednesday, May 4th. Zacks Investment Research upgraded shares of Prothena Co. PLC from a “sell” rating to a “hold” rating in a research note on Friday, May 6th. Wedbush reiterated an “outperform” rating and issued a $77.00 target price on shares of Prothena Co. PLC in a research note on Tuesday, July 5th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $95.00 target price on shares of Prothena Co. PLC in a research note on Monday, July 18th. Finally, Barclays PLC upped their target price on shares of Prothena Co. PLC from $60.00 to $70.00 and gave the stock an “overweight” rating in a research note on Thursday, August 4th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $76.60.

The firm’s 50-day moving average is $53.05 and its 200-day moving average is $43.88. The company’s market capitalization is $1.72 billion.

Prothena Co. PLC (NASDAQ:PRTA) last posted its quarterly earnings results on Tuesday, August 2nd. The company reported ($1.18) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.91) by $0.27. The company had revenue of $0.33 million for the quarter, compared to the consensus estimate of $0.39 million. The company’s quarterly revenue was up 22.2% on a year-over-year basis. Equities analysts anticipate that Prothena Co. PLC will post ($4.25) EPS for the current fiscal year.

In other Prothena Co. PLC news, insider Arthur W. Homan sold 9,375 shares of the firm’s stock in a transaction dated Wednesday, July 20th. The shares were sold at an average price of $52.14, for a total transaction of $488,812.50. Following the transaction, the insider now owns 9,375 shares of the company’s stock, valued at approximately $488,812.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

A number of hedge funds and institutional investors have bought and sold shares of PRTA. New York State Common Retirement Fund increased its position in Prothena Co. PLC by 4.0% in the fourth quarter. New York State Common Retirement Fund now owns 31,000 shares of the company’s stock worth $2,111,000 after buying an additional 1,200 shares during the period. Wells Fargo & Company MN increased its position in Prothena Co. PLC by 2,138.8% in the fourth quarter. Wells Fargo & Company MN now owns 245,639 shares of the company’s stock worth $16,730,000 after buying an additional 234,667 shares during the period. Finally, Jennison Associates LLC increased its position in Prothena Co. PLC by 0.5% in the fourth quarter. Jennison Associates LLC now owns 406,677 shares of the company’s stock worth $27,699,000 after buying an additional 1,912 shares during the period.

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis (PRX003).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.